DR. PHILLIP K RUPRECHT O.D.
Prescription History 1851440713
Optometrist in Mckinleyville, CA

NPI Status: Active since January 09, 2007

Contact Information

1933 CENTRAL AVE STE A
MCKINLEYVILLE, CA
ZIP 95519
Phone: (707) 839-2828
Fax: (707) 839-3715

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. PHILLIP K RUPRECHT O.D., an active Optometrist specialist practicing in Mckinleyville, CA. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 455 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 290 claims alone.

Medication Index


Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 43
30-Day Fills 67.7
Days Supply 1,992
CA State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills160.1
Peer Average Days Supply4,677
Conservative Utilization

This provider writes prescriptions for this formulation 44.9% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,882.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.78

State Avg Cost Per Claim

$43.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 35
30-Day Fills 66.0
Days Supply 1,976
CA State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills115.2
Peer Average Days Supply3,438
Conservative Utilization

This provider writes prescriptions for this formulation 36.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $655.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.73

State Avg Cost Per Claim

$32.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 290
30-Day Fills 399.9
Days Supply 10,900
CA State Average Benchmarks
Peer Average Claims159.0
Peer Average 30-Day Fills301.1
Peer Average Days Supply8,658
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 82.4% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,909.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.48

State Avg Cost Per Claim

$21.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Rhopressa

Generic Formulation: Netarsudil MesylateSpecialty: Optometry
Provider Metrics Summary
Total Claims 16
30-Day Fills 21.7
Days Supply 564
CA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills84.5
Peer Average Days Supply2,381
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,416.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$338.52

State Avg Cost Per Claim

$488.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). This medication is thought to work by increasing the flow of fluid out of the eye. This helps lower pressure inside the eye. Lowering high pressure inside the eye can help prevent loss of vision or blindness.

Rocklatan

Generic Formulation: Netarsudil Mesylat/LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 11
30-Day Fills 15.5
Days Supply 425
CA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills65.6
Peer Average Days Supply1,813
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,418.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$492.57

State Avg Cost Per Claim

$507.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil/latanoprost is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). Lowering high pressure inside the eye can help prevent vision loss or blindness.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Optometry
Provider Metrics Summary
Total Claims 20
30-Day Fills 34.3
Days Supply 1,030
CA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills55.9
Peer Average Days Supply1,619
Conservative Utilization

This provider writes prescriptions for this formulation 47.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,895.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$244.79

State Avg Cost Per Claim

$258.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 40
30-Day Fills 95.7
Days Supply 2,870
CA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills41.8
Peer Average Days Supply1,318
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 73.9% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $507.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.69

State Avg Cost Per Claim

$450.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. PHILLIP K RUPRECHT O.D. provides transparency into local medical care patterns within Mckinleyville, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.